Hologic, Inc. (HOLX)
Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 18.005
- Book/Share 21.5879
- PB 3.1115
- Debt/Equity 0.5209
- CurrentRatio 3.5547
- ROIC 0.0743
- MktCap 14939884230.0
- FreeCF/Share 4.3608
- PFCF 15.2728
- PE 27.0458
- Debt/Assets 0.2864
- DivYield 0
- ROE 0.1151
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HOLX | Argus | Hold | Buy | -- | $80 | Aug. 18, 2025 |
| Upgrade | HOLX | RBC Capital Mkts | Sector Perform | Outperform | -- | $87 | Aug. 6, 2025 |
| Upgrade | HOLX | Citigroup | Neutral | Buy | -- | $80 | July 9, 2025 |
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Reiterated | HOLX | Needham | -- | Buy | -- | $90 | Dec. 10, 2024 |
| Initiation | HOLX | Jefferies | -- | Hold | -- | $85 | Dec. 10, 2024 |
News
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more.
Read More
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test.
Read More
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Understanding Hologic (HOLX) Reliance on International Revenue
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.
Read More
Hologic: Soft Performance, But Cheap Enough
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Read More
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Read More
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
Read More
Hologic Brings in New Leadership: A Signal to Stay Put With the Stock?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
New Product Launches to Support HOLX Stock Amid Macro Issues
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets.
Read More
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
Read More
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Read More
Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software.
Read More
Two S&P 500 hidden gems to buy right now
Published: February 18, 2025 by: Finbold
Sentiment: Positive
Although the benchmark S&P 500's biggest names tend to dominate investor attention, the index also features lesser-known stocks with significant growth potential.
Read More
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
Read More
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen P. MacMillan
- Employees 7063